Testosterone propionate cycles cut

-->

  • Learn ▾
    • Lifestyle
      • Exercise & Fitness
      • Food & Nutrition
      • Sleep & Wellness
    • Aging
      • Aging & Bodily Changes
      • Testosterone
      • Human Growth Hormone
    • Men’s Health
      • General Health Topics
      • Health Numbers
  • Engage ▾
    • Workout Routines
      • Muscle Growth
      • Muscle Endurance
      • Strength & Endurance
    • Exercise Videos
      • Resistance
      • Lower Back Care
      • Abdominal
      • Stretching
    • My Health
      • BMI Calculator for Men
      • BMR Calculator for Men
      • Waist to Height Ratio Calculator
      • Health Check
  • Testosterone

Primary hypogonadism (congenital or acquired): Testicular failure due to diseases and conditions in the body such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter Syndrome, chemotherapy, or toxic damage from alcohol or heavy metals; these men usually have low serum testosterone levels and gonadotropins (FSH, LH) above normal range Hypogonadotropic hypogonadism (congenital or acquired): Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation; these men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Testosterone, like many anabolic steroids, was classified as a controlled substance in 1991. Testosterone is administered parenterally in normal and delayed-release (depot) forms. In September 1995, the FDA approved testosterone transdermal patches (Androderm), and many transdermal forms and brands are now available including implants, gels, and topical solutions. A testosterone buccal system, Striant, was FDA-approved in July 2003; Striant is a mucoadhesive product that adheres to the buccal mucosa and provides a controlled and sustained release of testosterone. In May 2014, the FDA approved an intranasal gel formulation of testosterone (Natesto). A transdermal patch (Intrinsa) for hormone replacement in women is under investigation; the daily dosages used in women are much lower than for products used in males. The FDA refused approval for Intrinsa in 2004 stating that more data regarding safety, especially in relation to cardiovascular and breast health, were required.

Testosterone propionate cycles cut

testosterone propionate cycles cut

Media:

testosterone propionate cycles cuttestosterone propionate cycles cuttestosterone propionate cycles cuttestosterone propionate cycles cuttestosterone propionate cycles cut